Filing Flows › Volitionrx (VNRX) › Q4 2025
Volitionrx (VNRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 31, 2026
Volitionrx (VNRX) reported revenue of $447K for the fourth quarter 2025 (Q4 2025), +133% from a year earlier and -29% from the quarter before.
Volitionrx, Q4 2025: revenue $447K (+133% year over year), net loss $6.3M, operating cash flow −$5.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $447K | -29% | +133% |
| Operating profit | −$4.8M | — | — |
| Net earnings | −$6.3M | — | — |
| Operating cash flow | −$5.5M | — | — |
What changed
Revenue was $447K in Q4 2025, up 133% year over year and down 29% from the previous quarter.
Operating costs exceeded revenue by $4.8M, an operating margin of -1077.9%. Total costs fell 12% while revenue rose 133%. The quarter ended with a net loss of $6.3M, wider than the previous quarter's $5.4M loss. Minority interests bore $32K of it: to shareholders the quarter was a loss of $6.3M.
Operating cash flow was −$5.5M. Non-cash charges added back $231K of depreciation and amortization. Working capital and other items added $580K. Capital expenditures of $11K exceeded it, leaving free cash flow of −$5.5M.
Questions
What was Volitionrx's revenue in the fourth quarter 2025?
Volitionrx (VNRX) reported revenue of $447K for the fourth quarter 2025 (Q4 2025), +133% from a year earlier and -29% from the quarter before.
Source: Volitionrx 10-K on SEC EDGAR.